A practical and safer model of nitrogen mustard injury in cornea
PLOS One · 2025
DOI: 10.1371/journal.pone.0327622 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ana M Sandoval-Castellanos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Vision Science, School of Medicine, University of California, Davis, California, United States of America. Hauptthemen laut MEDLINE: Mechlorethamine, Corneal Injuries, Disease Models, Animal, Cornea. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NEI NIH HHS, National Eye Institute.
Abstract (Originalsprache)
Purpose
Sulfur mustard (SM) is an alkylating agent used in warfare and terrorism that inflicts devastating ocular injuries. Although the clinical symptoms are well described, the underlying mechanisms are not fully understood, hindering the development of effective treatments. One major roadblock is the lack of a suitable model due to the extremely hazardous nature of SM, which requires strict safety measures. As a safer and practical alternative, we report a novel model that uses mechlorethamine (nitrogen mustard) gel, an FDA-approved topical chemotherapeutic administered by patients at home. Here we demonstrate its suitability to induce mustard corneal injury in any laboratory.
Methods
Ex vivo porcine corneas were injured with mechlorethamine gel. Hematoxylin-eosin staining and immunohistochemistry were performed to evaluate histopathology of SM-like corneal injuries: epithelium thickness and stromal separation, keratocyte and inflammatory cell counts, and expression of inflammation and fibrosis markers.
Results
This model showed the characteristic histopathology and expression of cyclooxygenase-2 (inflammation) and fibronectin-1 (fibrosis), which were consistent with other well-established SM-like corneal injury models.
Conclusion
Given its ease of implementation and safety, this mechlorethamine model could be used to study the full course of mustard corneal injuries. This model is expected to facilitate the understanding of mustard ocular injuries and the development of novel therapeutics. Translational relevance This model will allow safe evaluation of SM-like corneal injuries within 24 hours, facilitating the identification of early/new molecules that might help to develop novel treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology & Vision Science, School of Medicine, University of California, Davis, California, United States of America.
- Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, California, United States of America.
- VA Northern California Health Care System, Mather, California, United States of America.
- Department of Dermatology, Institute for Regenerative Cures, School of Medicine, University of California, Davis, California, United States of America.
ORCID-Profile: Ana M Sandoval-Castellanos, Tiffany M Dam, Min Zhao
Förderung
- BLRD VA
- NEI NIH HHS
- National Eye Institute
- Burns Family Audacious seed grants
- Air Force Office of Scientific Research
- California Institute for Regenerative Medicine
- VA Research Career Scientist
Zitieren
APA
Sandoval-Castellanos, A. M., Ke, Y., Dam, T. M., Maverakis, E. M., Mannis, M. J., Wang, X. J., & Zhao, M. (2025). A practical and safer model of nitrogen mustard injury in cornea. PLOS One. https://doi.org/10.1371/journal.pone.0327622
Vancouver
Sandoval-Castellanos AM, Ke Y, Dam TM, Maverakis EM, Mannis MJ, Wang XJ, et al. A practical and safer model of nitrogen mustard injury in cornea. PLOS One. 2025. doi:10.1371/journal.pone.0327622
BibTeX
@article{SandovalCastellanos2025,
author = {Sandoval-Castellanos, Ana M and Ke, Yao and Dam, Tiffany M and Maverakis, Emanual Michael and Mannis, Mark J and Wang, Xiao-Jing and Zhao, Min},
title = {A practical and safer model of nitrogen mustard injury in cornea},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0327622}
}
EUVIMED